Flurbiprofen in the prophylaxis of migraine
Glen D. Solomon, MDAddress reprint requests to G.D.S., Headache Center, A91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
Robert S. Kunkel, MD
Flurbiprofen, a nonsteroidal anti-inflammatory drug with effects on prostaglandin synthesis, platelet serotonin release, and beta-endorphin, was studied for efficacy in migraine prophylaxis. Twenty-three patients completed the 20-week, placebo-controlled, double-blind, crossover trial. Flurbiprofen, in a dose of 100 mg twice daily, and placebo were each given for 8 weeks, with a 2-week “washout” period between the treatment periods. Flurbiprofen significantly reduced migraine intensity (P < .05), total hours with migraine (P < .015), and the dosing frequency of relief medication (P < .015). Total hours with migraine decreased by 41%, and the use of relief medication decreased by 31%. The reduction in migraine frequency did not reach statistical significance (P < .10). Adverse effects were infrequent. Based on the overall improvement in migraine parameters, flurbiprofen can be recommended for use in migraine prophylaxis.